KPTI RSI Chart
Last 7 days
-7.9%
Last 30 days
9.5%
Last 90 days
69.5%
Trailing 12 Months
-59.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 148.1M | 146.0M | 145.9M | 146.0M |
2022 | 234.2M | 251.3M | 249.8M | 157.1M |
2021 | 113.2M | 102.3M | 118.7M | 209.8M |
2020 | 58.9M | 82.9M | 91.1M | 108.1M |
2019 | 33.0M | 35.6M | 38.3M | 40.9M |
2018 | 16.5M | 31.4M | 31.7M | 30.3M |
2017 | 222.0K | 567.8K | 1.3M | 1.6M |
2016 | 0 | 309.0K | 207.0K | 179.0K |
2015 | 0 | 208.0K | 262.0K | 266.0K |
2014 | 325.0K | 213.0K | 234.0K | 229.0K |
2013 | 833.0K | 433.0K | 399.0K | 387.0K |
2012 | 272.5K | 393.0K | 513.5K | 634.0K |
2011 | 0 | 0 | 0 | 152.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 05, 2024 | paulson richard a. | sold | -4,644 | 1.3 | -3,573 | president and ceo |
Mar 01, 2024 | mason michael | sold | -7,394 | 1.2 | -6,162 | evp, cfo & treasurer |
Mar 01, 2024 | paulson richard a. | sold | -23,248 | 1.2 | -19,374 | president and ceo |
Mar 01, 2024 | rangwala reshma | sold | -7,162 | 1.2 | -5,969 | evp & chief medical officer |
Mar 01, 2024 | mano michael | sold | -4,291 | 1.2 | -3,576 | svp, general counsel&secretary |
Mar 01, 2024 | cheng sohanya roshan | sold | -6,130 | 1.2 | -5,109 | evp & chief commercial officer |
Mar 01, 2024 | poulton stuart | sold | -7,386 | 1.2 | -6,155 | evp, chief development officer |
Feb 29, 2024 | mano michael | sold | -19,858 | 1.17 | -16,973 | svp, general counsel&secretary |
Feb 29, 2024 | mason michael | sold | -32,393 | 1.17 | -27,687 | evp, cfo & treasurer |
Feb 29, 2024 | cheng sohanya roshan | sold | -25,552 | 1.17 | -21,840 | evp & chief commercial officer |
Which funds bought or sold KPTI recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | unchanged | - | -1,425 | 2,595 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | reduced | -1.24 | -4,284,420 | 7,534,290 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 35.41 | -323,057 | 2,243,110 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -0.4 | -27,046 | 48,695 | -% |
Feb 26, 2024 | Virtu Financial LLC | new | - | 9,000 | 9,000 | -% |
Feb 16, 2024 | HARBOUR INVESTMENTS, INC. | unchanged | - | -617 | 1,125 | -% |
Feb 16, 2024 | GSA CAPITAL PARTNERS LLP | added | 311 | 1,260,000 | 2,022,000 | 0.17% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | unchanged | - | -41,000 | 76,000 | -% |
Feb 15, 2024 | WEXFORD CAPITAL LP | new | - | 23,597 | 23,597 | -% |
Feb 15, 2024 | BARCLAYS PLC | reduced | -15.82 | -706,000 | 838,000 | -% |
Unveiling Karyopharm Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Karyopharm Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.3B | 6.8B | -8.96 | 6.17 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.4B | 1.8B | -44.17 | 10.64 | ||||
BMRN | 16.7B | 2.4B | 99.73 | 6.91 | ||||
INCY | 12.8B | 3.7B | 21.46 | 3.47 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.34 | 17.78 | ||||
BBIO | 5.4B | - | -8.31 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.68 | 13.86 | ||||
ARWR | 3.6B | 240.7M | -11.98 | 14.77 | ||||
ACAD | 3.0B | 726.4M | -48.93 | 4.13 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.85 | 4.82 | ||||
NVAX | 678.8M | 983.7M | -1.25 | 0.69 | ||||
CRBP | 373.2M | 881.7K | -8.37 | 466.16 | ||||
INO | 304.5M | 4.9M | -2.25 | 62.57 | ||||
IBIO | 11.8M | 2.1M | -0.43 | 2.14 |
Karyopharm Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | -6.3% | 33,747,000 | 36,009,000 | 37,579,000 | 38,698,000 | 33,580,000 | 36,145,000 | 39,679,000 | 47,670,000 | 126,269,000 | 37,689,000 | 22,601,000 | 23,260,000 | 35,100,000 | 21,333,000 | 33,514,000 | 18,138,000 | 18,096,000 | 13,149,000 | 9,493,000 | 4,849,500 | 206,000 |
Operating Expenses | 6.4% | 71,555,000 | 67,269,000 | 67,152,000 | 69,597,000 | 67,449,000 | 66,984,000 | 82,587,000 | 82,256,000 | 79,307,000 | 81,501,000 | 71,649,000 | 75,633,000 | 72,166,000 | 68,442,000 | 73,833,000 | 65,494,000 | 61,362,000 | 52,550,000 | 51,179,000 | 65,077,000 | 57,661,000 |
S&GA Expenses | -0.4% | 30,688,000 | 30,805,000 | 34,481,000 | 35,907,000 | 34,649,000 | 34,645,000 | 37,339,000 | 38,768,000 | 34,562,000 | 35,104,000 | 36,530,000 | 37,650,000 | 33,929,000 | 30,967,000 | 30,843,000 | 30,678,000 | 28,389,000 | 25,267,000 | 24,662,000 | 27,103,000 | 18,771,000 |
R&D Expenses | 10.8% | 39,381,000 | 35,553,000 | 31,477,000 | 32,339,000 | 30,932,000 | 31,359,000 | 44,309,000 | 42,062,000 | 44,003,000 | 45,808,000 | 33,981,000 | 37,050,000 | 37,185,000 | 37,037,000 | 42,594,000 | 33,997,000 | 31,579,000 | 26,270,000 | 26,517,000 | 37,974,000 | 38,890,000 |
EBITDA Margin | -2.5% | -0.81 | -0.79 | -0.80 | -0.90 | -0.89 | -0.24 | -0.29 | -0.34 | -0.46 | -1.51 | -1.79 | -1.53 | - | - | - | - | - | - | - | - | - |
Interest Expenses | 2.2% | 6,208,000 | 6,073,000 | 5,784,000 | 5,758,000 | 5,885,000 | 6,114,000 | 6,313,000 | 6,684,000 | 7,940,000 | 8,010,000 | 5,001,000 | 5,095,000 | 7,072,000 | 6,801,000 | 6,758,000 | 6,509,000 | 6,467,000 | 3,093,000 | 3,089,000 | 2,998,000 | - |
Income Taxes | 983.3% | 130,000 | 12,000 | 127,000 | 54,000 | 73,000 | 45,000 | 121,000 | 130,000 | -89,000 | 106,000 | 134,000 | 149,000 | 53,000 | 44,000 | 137,000 | 66,000 | 2,000 | 20,000 | 8,000 | 10,000 | 17,000 |
Earnings Before Taxes | -20.9% | -41,707,000 | -34,494,000 | -32,503,000 | -34,072,000 | -38,433,000 | -36,279,000 | -48,941,000 | -41,269,000 | 38,599,000 | -51,706,000 | -53,448,000 | -57,265,000 | -43,359,000 | -53,451,000 | -46,289,000 | -52,865,000 | -48,645,000 | -41,347,000 | -43,407,000 | -66,151,000 | -58,193,000 |
EBT Margin | -2.2% | -0.98 | -0.96 | -0.97 | -1.06 | -1.05 | -0.35 | -0.41 | -0.46 | -0.59 | -1.73 | -2.03 | -1.77 | - | - | - | - | - | - | - | - | - |
Net Income | -21.2% | -41,837,000 | -34,506,000 | -32,630,000 | -34,126,000 | -38,506,000 | -36,324,000 | -49,062,000 | -41,399,000 | 38,720,000 | -51,812,000 | -53,582,000 | -57,414,000 | -43,421,000 | -53,495,000 | -46,426,000 | -52,931,000 | -48,647,000 | -41,367,000 | -43,415,000 | -66,161,000 | -58,210,000 |
Net Income Margin | -2.3% | -0.98 | -0.96 | -0.97 | -1.07 | -1.05 | -0.35 | -0.41 | -0.46 | -0.59 | -1.74 | -2.03 | -1.77 | - | - | - | - | - | - | - | - | - |
Free Cashflow | 37.1% | -18,585,000 | -29,530,000 | -25,698,000 | -18,910,000 | -26,843,000 | -28,409,000 | -35,144,000 | -59,276,000 | 25,268,000 | -23,960,000 | -55,748,000 | -52,888,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -10.9% | 240 | 270 | 298 | 326 | 358 | 231 | 256 | 294 | 305 | 254 | 287 | 275 | 313 | 338 | 380 | 416 | 295 | 298 | 238 | 287 | 341 |
Current Assets | -11.1% | 234 | 263 | 291 | 319 | 350 | 223 | 242 | 277 | 276 | 242 | 274 | 256 | 277 | 285 | 318 | 371 | 279 | 281 | 223 | 271 | 335 |
Cash Equivalents | 19.6% | 52.00 | 44.00 | 81.00 | 84.00 | 135 | 71.00 | 82.00 | 153 | 190 | 137 | 141 | 88.00 | 89.00 | 82.00 | 103 | 202 | 131 | 168 | 76.00 | 84.00 | 119 |
Inventory | -2.0% | 3.00 | 3.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 2.00 | 2.00 | 1.00 | 0.00 | 0.00 | - | - | - |
Net PPE | -11.7% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 |
Liabilities | 1.7% | 377 | 370 | 369 | 371 | 375 | 372 | 373 | 377 | 385 | 380 | 370 | 315 | 263 | 254 | 250 | 250 | 245 | 238 | 156 | 166 | 158 |
Current Liabilities | 11.9% | 69.00 | 62.00 | 59.00 | 62.00 | 66.00 | 62.00 | 63.00 | 66.00 | 74.00 | 69.00 | 58.00 | 62.00 | 60.00 | 53.00 | 51.00 | 50.00 | 46.00 | 39.00 | 32.00 | 44.00 | 47.00 |
Shareholder's Equity | -Infinity% | -136 | - | - | - | -16.66 | - | - | - | -79.67 | - | - | - | 51.00 | 84.00 | 130 | 166 | 50.00 | 60.00 | 82.00 | 121 | 183 |
Retained Earnings | -2.9% | -1,487 | -1,445 | -1,410 | -1,378 | -1,343 | -1,305 | -1,269 | -1,220 | -1,178 | -1,217 | -1,165 | -1,111 | -15.00 | -1,026 | -972 | -926 | -873 | -824 | -783 | -739 | -673 |
Additional Paid-In Capital | 0.4% | 1,351 | 1,346 | 1,340 | 1,333 | 1,328 | 1,166 | 1,153 | 1,137 | 1,099 | 1,091 | 1,082 | 1,072 | 1,120 | 1,109 | 1,102 | 1,093 | 923 | 885 | 866 | 861 | 857 |
Shares Outstanding | 0.3% | 115 | 115 | 114 | 114 | 113 | 80.00 | 79.00 | 78.00 | 75.00 | 75.00 | 75.00 | 75.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 201 | - | - | - | 351 | - | - | - | 739 | - | - | - | 1,320 | - | - | - | 344 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 37.1% | -18,585 | -29,530 | -25,698 | -18,910 | -26,843 | -28,370 | -35,144 | -59,197 | 25,475 | -23,955 | -55,748 | -52,888 | -30,634 | -44,312 | -40,277 | -45,011 | -39,489 | -36,506 | -48,204 | -66,623 | -48,172 |
Share Based Compensation | 2.0% | 5,182 | 5,078 | 6,060 | 5,389 | 6,173 | 6,797 | 15,093 | 7,336 | 6,869 | 7,420 | 8,135 | 7,359 | 6,314 | 6,513 | 6,428 | 5,152 | 3,549 | 3,719 | 4,116 | 3,907 | 3,897 |
Cashflow From Investing | 449.3% | 26,843 | -7,685 | 21,170 | -32,388 | -65,298 | 11,673 | -36,596 | -14,035 | 30,770 | 21,426 | 46,458 | 43,186 | 31,397 | 21,431 | -60,034 | -46,479 | -33,519 | 40,175 | 39,803 | 31,991 | -103,110 |
Cashflow From Financing | - | 264 | - | 860 | - | 155,843 | 5,799 | 1,313 | 30,783 | 896 | 16.00 | 62,060 | 10,676 | 3,968 | 1,240 | 2,046 | 164,829 | 34,936 | 88,822 | 395 | 152 | 167,776 |
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues: | |||
Revenue from contract with customer, license and other revenue | $ 146,033 | $ 157,074 | $ 209,819 |
Operating expenses: | |||
Research and development | 138,750 | 148,662 | 160,842 |
Selling, general and administrative | 131,881 | 145,401 | 143,846 |
Total operating expenses | 275,573 | 299,276 | 308,090 |
Loss from operations | (129,540) | (142,202) | (98,271) |
Other income (expense): | |||
Interest income | 10,943 | 2,359 | 582 |
Interest expense | (23,823) | (24,996) | (26,046) |
Other expense, net | (356) | (83) | (85) |
Total other expense, net | (13,236) | (22,720) | (25,549) |
Loss before income taxes | (142,776) | (164,922) | (123,820) |
Income tax provision | (323) | (369) | (268) |
Net loss | $ (143,099) | $ (165,291) | $ (124,088) |
Net loss per share - basic | $ (1.25) | $ (2.02) | $ (1.65) |
Net loss per share - diluted | $ (1.25) | $ (2.02) | $ (1.65) |
Weighted-average number of common shares outstanding used to compute net loss per share - basic | 114,221,000 | 81,871,000 | 75,218,000 |
Weighted-average number of common shares outstanding used to compute net loss per share - diluted | 114,221,000 | 81,871,000 | 75,218,000 |
Product [Member] | |||
Revenues: | |||
Revenue from contract with customer, license and other revenue | $ 112,011 | $ 120,445 | $ 98,436 |
Operating expenses: | |||
Cost of sales | 4,942 | 5,213 | 3,402 |
License and Other [Member] | |||
Revenues: | |||
Revenue from contract with customer, license and other revenue | $ 34,022 | $ 36,629 | $ 111,383 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 52,231 | $ 135,188 |
Investments | 139,212 | 142,779 |
Accounts receivable,net | 26,962 | 47,086 |
Inventory | 3,043 | 4,224 |
Prepaid expenses and other current assets | 11,813 | 19,821 |
Restricted cash | 660 | 1,064 |
Total current assets | 233,921 | 350,162 |
Property and equipment, net | 606 | 1,139 |
Operating lease right-of-use assets | 4,276 | 6,238 |
Restricted cash | 301 | 633 |
Other assets | 1,334 | 0 |
Total assets | 240,438 | 358,172 |
Current liabilities: | ||
Accounts payable | 3,123 | 2,773 |
Accrued expenses | 61,394 | 58,415 |
Operating lease liabilities | 3,308 | 2,872 |
Other current liabilities | 1,654 | 1,848 |
Total current liabilities | 69,479 | 65,908 |
Convertible senior notes | 170,919 | 170,105 |
Deferred royalty obligation | 132,479 | 132,718 |
Operating lease liabilities, net of current portion | 2,789 | 6,097 |
Other liabilities | 978 | 0 |
Total liabilities | 376,644 | 374,828 |
Stockholders' deficit | ||
Preferred stock, $0.0001 par value; 5,000 shares authorized; none issued and outstanding | 0 | 0 |
Common stock, $0.0001 par value; 4000,000 shares authorized; 114,915 shares issued and outstanding at December 31, 2023; 200,000 shares authorized; 113,213 shares issued and outstanding at December 31, 2022 | 12 | 12 |
Additional paid-in capital | 1,350,981 | 1,327,909 |
Accumulated other comprehensive loss | (161) | (638) |
Accumulated deficit | (1,487,038) | (1,343,939) |
Total stockholders' deficit | (136,206) | (16,656) |
Total liabilities and stockholders' deficit | $ 240,438 | $ 358,172 |